Complement activation in patients with COVID-19: A novel therapeutic target
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the coronavirus responsible for the current pandemic of coronavirus disease 2019 (COVID-19), whose very broad clinical spectrum ranges from minor signs and symptoms such as cough and mild fever to severe pneumonia with dyspnea, tachypnea, and impaired gas exchange, leading to severe and life-threatening manifestations in approximately 15% of infected patients.1 Increased levels of proinflammatory cytokines and coagulation activation markers2 indicate that a sustained inflammatory response to viral infection and the related prothrombotic state are involved in the development of these clinical manifestations.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Massimo Cugno, Pier Luigi Meroni, Roberta Gualtierotti, Samantha Griffini, Elena Grovetti, Adriana Torri, Mauro Panigada, Stefano Aliberti, Francesco Blasi, Francesco Tedesco, Flora Peyvandi Tags: Letter to the Editor Source Type: research
More News: Allergy | Allergy & Immunology | Coronavirus | Cough | COVID-19 | Pandemics | Pneumonia | Respiratory Medicine | SARS